newsfilter
← Latest News
ACCESS Newswire·

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end